2-((4-(thiomorpholinosulfonyl)phenyl)carbamoyl)benzoic acid | 501700-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((4-(thiomorpholinosulfonyl)phenyl)carbamoyl)benzoic acid
• 英文别名: LASSBio-596；2-{[4-(Thiomorpholine-4-sulfonyl)phenyl]carbamoyl}benzoic acid；2-[(4-thiomorpholin-4-ylsulfonylphenyl)carbamoyl]benzoic acid
• CAS: 501700-16-9
• 化学式: C₁₈H₁₈N₂O₅S₂
• 分子量: 406.483
• InChiKey: YEZCXXCFGZJZRO-UHFFFAOYSA-N

物化性质

• 密度：
  1.474±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  138
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-苯基邻苯二甲酰亚胺 在 氯磺酸 、 lithium hydroxide 、 五氯化磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-((4-(thiomorpholinosulfonyl)phenyl)carbamoyl)benzoic acid
  参考文献：
  名称：

  Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues

  摘要：

  This paper describes the synthesis and anti-inflammatory activity of new N-phenyl-phthalimide sulfonamides (3a-e) and the isosters N-phenyl-phthalimide amides (4a-e), designed as hybrids of thalidomide (1) and aryl sulfonamide phosphodiesterase inhibitor (2), In these series, compound 3e (LASSBio 468). having a sulfonyl-thiomorpholine moiety, showed potent inhibitory activity on LPS-induced neutrophil recruitment with ED50 = 2.5 mg kg(-1), which was correlated with its inhibitory effect on TNF-alpha level. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00152-9

文献信息

• Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response
  作者：Maria Barbosa、Thiago Ramos、Ana de Arantes、Marco Martins、Patrícia Silva、Eliezer Barreiro、Lídia Lima

  DOI：10.3390/molecules171214651

  日期：——

  In this paper we report the design, synthesis and pharmacological evaluation of a new series of phenyl sulfonamide derivatives 2a–h and 3–8 planned by structural modification on the anti-inflammatory prototype LASSBio-468 (1). Among the synthesized analogues, the tetrafluorophthalimide LASSBio-1439 (2e) stands out showing an in vitro anti-TNF-α effect similar to the standard thalidomide. The relevance

  在本文中，我们报告了一系列新的苯基磺酰胺衍生物 2a-h 和 3-8 的设计、合成和药理学评价，这些衍生物计划通过对抗炎原型 LASSBio-468 进行结构修饰 (1)。在合成的类似物中，四氟邻苯二甲酰亚胺 LASSBio-1439 (2e) 表现出与标准沙利度胺相似的体外抗 TNF-α 作用。邻苯二甲酰亚胺核四氟化的相关性也通过 2e 在肺部炎症小鼠模型中通过口服给药的抗炎特性得到证实。相应的四氟羧酰胺代谢物 LASSBio-1454 (15) 由衍生物 2e 的部分水解产生，在体外表现出显着的效果和显着的体内抗炎活性。
• TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR
  申请人：Progenity, Inc.

  公开号：US20200323772A1

  公开（公告）日：2020-10-15

  This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.
• TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR
  申请人：Progenity, Inc.

  公开号：US20210031012A1

  公开（公告）日：2021-02-04

  This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.
• [EN] TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR<br/>[FR] TRAITEMENT DE MALADIE INFLAMMATOIRE FAISANT APPEL À UN DISPOSITIF INGÉRABLE POUR LIBÉRER UN IMMUNOMODULATEUR
  申请人：PROGENITY INC

  公开号：WO2019036382A1

  公开（公告）日：2019-02-21

  This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.
• [EN] TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR<br/>[FR] TRAITEMENT D'UNE MALADIE DU TRACTUS GASTRO-INTESTINAL AVEC UN INHIBITEUR DE PDE4
  申请人：PROGENITY INC

  公开号：WO2019147824A1

  公开（公告）日：2019-08-01

  This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.